Escherichia coli, Klebsiella oxytoca, Klebsiella aerogenes, Klebsiella pneumoniae and Enterobacter spp
Providencia, Proteus, Morganella, Citrobacter, and Serratia
Other Enterobacterales
MIC: ≥4 µg/ml doripenem or ≥4 µg/ml imipenem or ≥4 µg/ml meropenem ≥2 µg/ml ertapenem
MTPHL will perform testing for Carbapenemase Resistant Enterobacterales (CRE) and forward to our Regional Lab if needed.
MIC: ≥8 µg/ml imipenem or ≥8 µg/ml meropenem or ≥8 µg/ml doripenem
MTPHL will perform testing for Carbapenemase Resistant Pseudomonas aeruginosa (CRPA) and forward to our Regional Lab if needed.
Please send antimicrobial sensitivities with the submitted isolate.
MIC: ≥8 µg/ml imipenem or ≥8 µg/ml meropenem or ≥8 µg/ml doripenem
MTPHL will perform testing for Carbapenemase Resistant Acinetobacter baumannii (CRAB) and forward to our Regional Lab if needed.
Please send antimicrobial sensitivities with the submitted isolate.
All confirmed azole-resistant A. fumigatus isolates are first priority.
Please send antimicrobial sensitivities with the submitted isolate.
Second priority are isolates from any specimen source, especially invasive sites.
Species identification, especially C. auris
Isolates will be submitted to our Regional Lab for further testing
MIC: ≥32 µg/ml vancomycin and ≥8 µg/ml daptomycin and ≥8 µg/ml linezolid
Isolates will be confirmed and submitted to our Regional Lab for further testing
Please send antimicrobial sensitivities with the submitted isolate
All isolates from sterile sites.
MTPHL will confirm, test for serotype with antisera and forward to a Regional Lab for serotyping by PCR if needed
All isolates.
All isolates.
MTPHL will confirm and perform yearly AST testing which is forwarded to CDC for surveillance purposes.
All test requests require preauthorization before specimen submission, please contact our HAI/AR Epidemiologist Erika Baldry at (406)444-0275 or Erika.Baldry@mt.gov.
Isolates or specimens are sent to MTPHL and forwarded to a Regional Laboratory for testing for susceptibility to azithromycin, cefixime and ceftriaxone by gradient strip diffusion, in a CLIA-compliant manner, results returned to submitters.
All isolates from sterile sites.
MTPHL will confirm, test for serotype B with antisera and forward to a Regional Lab for serotyping by PCR (if isolate is B negative).
Resistant to all drugs tested by the submitting clinical laboratory.
Non-susceptible OR intermediate to all drugs tested by the submitting clinical laboratory.
Isolates will be submitted to our Regional Laboratory for Expanded AST testing (ExAST). Has three reportable drugs resulted to submitting laboratory: Aztreonam, Aztreonam-avibactam and Ceftazidime-avibactam.
Isolates not susceptible to all β-lactams tested, including either ceftazidime/avibactam or meropenem/vaborbactam or Possess at least one Metallo Beta-lactamase gene (blaNDM, blaVIM or blaIMP) confirmed by a molecular test.
MIC: ≥8 µg/ml vancomycin.
MTPHL will confirm and submit isolate to our Regional Lab for further testing.
Please send antimicrobial sensitivities with the submitted isolate.
All isolates from a sterile site.